- Home
- ASTH vs TARS Comparison
ASTH vs TARS Comparison
Compare ASTH & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- TARS
- Stock Information
- Founded
- ASTH 1994
- TARS 2016
- Country
- ASTH United States
- TARS United States
- Employees
- ASTH N/A
- TARS N/A
- Industry
- ASTH Professional Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ASTH Consumer Discretionary
- TARS Health Care
- Exchange
- ASTH Nasdaq
- TARS Nasdaq
- Market Cap
- ASTH 1.7B
- TARS 1.7B
- IPO Year
- ASTH N/A
- TARS 2020
- Fundamental
- Price
- ASTH $29.33
- TARS $54.21
- Analyst Decision
- ASTH Strong Buy
- TARS Strong Buy
- Analyst Count
- ASTH 8
- TARS 7
- Target Price
- ASTH $53.29
- TARS $67.14
- AVG Volume (30 Days)
- ASTH 502.0K
- TARS 678.3K
- Earning Date
- ASTH 08-07-2025
- TARS 08-06-2025
- Dividend Yield
- ASTH N/A
- TARS N/A
- EPS Growth
- ASTH N/A
- TARS N/A
- EPS
- ASTH 0.52
- TARS N/A
- Revenue
- ASTH $2,419,115,000.00
- TARS $295,521,000.00
- Revenue This Year
- ASTH $46.18
- TARS $122.94
- Revenue Next Year
- ASTH $23.94
- TARS $44.14
- P/E Ratio
- ASTH $56.08
- TARS N/A
- Revenue Growth
- ASTH 51.97
- TARS 254.45
- 52 Week Low
- ASTH $21.20
- TARS $24.95
- 52 Week High
- ASTH $63.20
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- ASTH 67.58
- TARS 78.63
- Support Level
- ASTH $28.73
- TARS $40.55
- Resistance Level
- ASTH $30.78
- TARS $42.11
- Average True Range (ATR)
- ASTH 1.55
- TARS 2.14
- MACD
- ASTH 0.85
- TARS 1.38
- Stochastic Oscillator
- ASTH 84.86
- TARS 94.81
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.